Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer

Conclusion:
The HOXC11 target gene, PSAP, is an AR activator which facilitates adaptation to a more invasive phenotype in vitro. These findings have particular relevance to the development of resistance to AI therapy which is an emerging clinical issue. PSAP is a secreted biomarker which has potential in identifying patients failing to exhibit sustained response to hormonal treatment.

Source: Breast Cancer Research - September 4, 2015 Category: Cancer & Oncology Authors: Azlena AliLaura CreeveyYuan HaoDamian McCartanPeadar O¿GaoraArnold HillLeonie YoungMarie McIlroy Source Type: research